Revenue and Deferred Revenue - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Aug. 31, 2019
Deferred Revenue Arrangement [Line Items]
Revenue	$ 6,617,000	$ 656,000
Deferred revenue	376,000	250,000		$ 0
Revenue recognized	$ 250,000	0
Revenue Benchmark | Geographic Concentration Risk | Asia
Deferred Revenue Arrangement [Line Items]
Concentration risk, percentage	21.00%
Product
Deferred Revenue Arrangement [Line Items]
Revenue	$ 3,577,000	0
Deferred revenue	400,000	0
Service
Deferred Revenue Arrangement [Line Items]
Revenue	500,000	0
Revenue recognized	0
Service | Pharmaceutical company
Deferred Revenue Arrangement [Line Items]
Deferred revenue		300,000
Deferred revenue, consideration of agreement		500,000
Grant and other
Deferred Revenue Arrangement [Line Items]
Revenue	223,000	656,000
Grant and other | Biotechnology company
Deferred Revenue Arrangement [Line Items]
Revenue	0	300,000
Grant and other | NH Grant
Deferred Revenue Arrangement [Line Items]
Deferred revenue			$ 900,000		$ 1,100,000
Revenue recognized	$ 200,000	$ 400,000